Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of rilzabrutinib versus placebo in adults with active IgG4-related disease
MOH_2025-09-16_014347Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rilzabrutinib in IgG4-related disease (IgG4-RD) (2 arms), sponsored by Sanofi. Primary endpoint: Time to clinical IgG4-related disease flare. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
rilzabrutinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on MOH_2025-09-16_014347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-16_014347.